Literature DB >> 20043014

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.

Phyllis I Spuls1, Lidian L A Lecluse, Marie-Louise N F Poulsen, Jan D Bos, Robert S Stern, Tamar Nijsten.   

Abstract

A large number of clinical measures of psoriasis are used in clinical trials and daily practice. These measures lack uniformity and validation. However, valid outcome and severity measures for psoriasis are a prerequisite for fully informative clinical research and evidence-based medicine. The purpose of this study was to identify all clinical measures of psoriasis severity and outcome in use and to evaluate the quality of these measures using clinimetric criteria; we identified 53 separate clinical measures, which were regrouped into 11 measures for quality analysis. No measure could be scored on all items used in the clinimetric analysis. The Lattice System Physician's Global Assessment and Physician's Global Assessment were most highly noted. We conclude that none of the psoriasis measures is adequately validated. The Psoriasis Area and Severity Index is the most commonly used clinical measure in research, but it has substantial limitations such as low response distribution, no consensus on interpretability, and low responsiveness in mild disease. Nevertheless, because of its widespread use the Psoriasis Area and Severity Index permits some degree of comparison of results among clinical trials. Overall, no best instrument was identified, and different situations may call for different measures.

Entities:  

Mesh:

Year:  2009        PMID: 20043014     DOI: 10.1038/jid.2009.391

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  50 in total

1.  In-vivo imaging of psoriatic lesions with polarization multispectral dermoscopy and multiphoton microscopy.

Authors:  Dimitrios Kapsokalyvas; Riccardo Cicchi; Nicola Bruscino; Domenico Alfieri; Francesca Prignano; Daniela Massi; Torello Lotti; Francesco S Pavone
Journal:  Biomed Opt Express       Date:  2014-06-24       Impact factor: 3.732

Review 2.  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Authors:  Emilie Sbidian; Anna Chaimani; Ignacio Garcia-Doval; Giao Do; Camille Hua; Canelle Mazaud; Catherine Droitcourt; Carolyn Hughes; John R Ingram; Luigi Naldi; Olivier Chosidow; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2017-12-22

Review 3.  Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment.

Authors:  Wolf-Henning Boehncke; Nicolo Costantino Brembilla
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

Review 4.  Efficacy of ω-3 supplementation in patients with psoriasis: a meta-analysis of randomized controlled trials.

Authors:  Cain C T Clark; Mohsen Taghizadeh; Mina Nahavandi; Sadegh Jafarnejad
Journal:  Clin Rheumatol       Date:  2019-02-18       Impact factor: 2.980

5.  CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis: A Randomized Clinical Trial.

Authors:  Ari M Goldminz; Mayte Suárez-Fariñas; Andrew C Wang; Nicole Dumont; James G Krueger; Alice B Gottlieb
Journal:  JAMA Dermatol       Date:  2015-08       Impact factor: 10.282

6.  Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.

Authors:  Joel M Gelfand; Joy Wan; Kristina Callis Duffin; Gerald G Krueger; Robert E Kalb; Jamie D Weisman; Brian R Sperber; Michael B Stierstorfer; Bruce A Brod; Stephen M Schleicher; Bruce F Bebo; Andrea B Troxel; Daniel B Shin; Jane M Steinemann; Jennifer Goldfarb; Howa Yeung; Abby S Van Voorhees
Journal:  Arch Dermatol       Date:  2012-04

7.  Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.

Authors:  Kristina Callis Duffin; Joseph F Merola; Robin Christensen; John Latella; Amit Garg; Alice B Gottlieb; April W Armstrong
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

8.  Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis.

Authors:  Misha Rosenbach; Howa Yeung; Emily Y Chu; Ellen J Kim; Aimee S Payne; Junko Takeshita; Carmela C Vittorio; Karolyn A Wanat; Victoria P Werth; Joel M Gelfand
Journal:  JAMA Dermatol       Date:  2013-05       Impact factor: 10.282

9.  Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity.

Authors:  J C Cappelleri; A G Bushmakin; J Harness; C Mamolo
Journal:  Qual Life Res       Date:  2013-03-09       Impact factor: 4.147

10.  Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force.

Authors:  Marc K Walton; John H Powers; Jeremy Hobart; Donald Patrick; Patrick Marquis; Spiros Vamvakas; Maria Isaac; Elizabeth Molsen; Stefan Cano; Laurie B Burke
Journal:  Value Health       Date:  2015-08-24       Impact factor: 5.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.